---
document_datetime: 2025-07-14 17:03:21
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/plavix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: plavix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3047569
conversion_datetime: 2025-12-27 20:47:52.601923
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Plavix

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 11/07/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000285292   | variations. A.ADMINISTRATIVE CHANGES-A.7 Deletionofmanufacturingsitesfor anactive substance,intermediateorfinishedproduct, packaging site, manufacturer responsible for batchrelease,sitewherebatchcontroltakes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)*- Accepted B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused in themanufacturingprocessof the active substance or changeinthemanufacturer (includingwhererelevantquality control testingsites)oftheactivesubstance,where no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer- Accepted   | PL   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|